Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 10Mastocytosis, Systemic 3Leukemia, Mast-Cell 2Aggression 2Recurrence 1Myelodysplastic Syndromes 1Mastocytosis 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Leukemia 1Congenital Abnormalities 1Blast Crisis 1

Interventions

Cyclophosphamide 178Cytarabine 110fludarabine phosphate 102Methotrexate 98Busulfan 90Filgrastim 80Rituximab 72Peripheral Blood Stem Cell Transplantation 69Cyclosporine 60Radiotherapy 57Etoposide 57Mycophenolic Acid 56Antilymphocyte Serum 56fludarabine 55Tacrolimus 55Vincristine 47Whole-Body Irradiation 44Melphalan 42Dexamethasone 39Granulocyte Colony-Stimulating Factor 38sargramostim 34Methylprednisolone 34Alemtuzumab 34Daunorubicin 33Imatinib Mesylate 32Mercaptopurine 28Prednisone 26Idarubicin 26Doxorubicin 25Leucovorin 24

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Leukemia × midostaurin × Clear all
NCT00782067 2018-11-15

Efficacy and Safety of Midostaurin in Patients With Aggressive Systemic Mastocytosis or Mast Cell Leukemia

Novartis

Phase 2 Completed
116 enrolled 16 charts
LymphoidMyeloidOther hematologic neoplasm

Aggression, Leukemia, Leukemia, Mast-Cell, Mastocytosis, Systemic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡